Cartesian Therapeutics, Inc.
RNACNext catalyst
Descartes-08
Systemic Lupus Erythematosus (SLE)
Get an email about RNAC's next catalysts
Track Cartesian Therapeutics (RNAC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 3 readout).See the timeline
2 upcoming, 1 past
Descartes-08 Phase 2 Est. Readout (SLE-001)
Primary completion for Descartes-08 trial (NCT07089121) in Childhood-onset Systemic Lupus Erythematous
SourceDecartes-08 Phase 3 Est. Readout
Primary completion for Decartes-08 trial (NCT06799247) in Myasthaenia Gravis
SourceMarket Overview
Stock performance and key metrics
Decartes-08
Myasthaenia Gravis
Descartes-08
Systemic Lupus Erythematosus (SLE)
Descartes 11
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Decartes-08 | Phase 3 | Myasthaenia Gravis | - | - |
Descartes-08 | Phase 2 | Systemic Lupus Erythematosus (SLE) | - | - |
Descartes 11 | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in Cartesian Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cartesian Therapeutics, Inc.'s (RNAC) pipeline across Phase 3, Phase 2. Its lead program is Decartes-08 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cartesian Therapeutics, Inc.'s next FDA catalyst?→
Cartesian Therapeutics, Inc.'s (RNAC) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RNAC biotech catalysts?→
Add RNAC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cartesian Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.